![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC) Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC)](https://publichealthcollaborative.org/wp-content/uploads/2022/10/ENG_Twitter_updated-booster-doses-2-1024x576.png)
Updated Toolkit: COVID-19 Booster Dose Messaging and Outreach Tools - Public Health Communications Collaborative (PHCC)
![Bivalent COVID-19 booster vaccine receives MHRA approval - Hospital Pharmacy EuropeHospital Pharmacy Europe Bivalent COVID-19 booster vaccine receives MHRA approval - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2022/08/Bivalent-COVID-19-booster-vaccine-receives-MRHA-approval.jpg)
Bivalent COVID-19 booster vaccine receives MHRA approval - Hospital Pharmacy EuropeHospital Pharmacy Europe
![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/attachment/b611936d-5800-49ea-ab56-e932ddaa3aa7/gr1_lrg.jpg)